1 Jan 2007 Jahr - Food and Drug Administration Amendments Act of 2007
Beschreibung:
Specifically authorized FDA to require manufacturers post-marketing clinical studies to monitor for risks infected during the pre-market approval process
Also required REMS programs where necessary. What is a REMS program?
Zugefügt zum Band der Zeit:
Datum: